标题
TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis
作者
关键词
-
出版物
Expert Review of Clinical Immunology
Volume 15, Issue 12, Pages 1303-1312
出版商
Informa UK Limited
发表日期
2019-10-26
DOI
10.1080/1744666x.2020.1685382
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Infliximab in inflammatory bowel disease
- (2019) Konstantinos Papamichael et al. Therapeutic Advances in Chronic Disease
- Update upon the infection risk in patients receiving TNF alpha inhibitors
- (2019) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- The pathogenesis of psoriatic arthritis
- (2018) Douglas J Veale et al. LANCET
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Role of comorbidities in spondyloarthritis including psoriatic arthritis
- (2018) Silvia Scriffignano et al. CLINICAL RHEUMATOLOGY
- Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
- (2018) Sara Rundquist et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- (2018) Jasvinder A. Singh et al. Arthritis & Rheumatology
- Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis
- (2017) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Adalimumab for the treatment of uveitis
- (2017) Kara C. LaMattina et al. Expert Review of Clinical Immunology
- Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort
- (2017) Ennio Lubrano et al. JOURNAL OF RHEUMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases
- (2017) Michael Croft et al. Nature Reviews Rheumatology
- Psoriatic Arthritis
- (2017) Christopher T. Ritchlin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor necrosis factor inhibitors in psoriatic arthritis
- (2017) Santhi Mantravadi et al. Expert Review of Clinical Pharmacology
- Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics
- (2016) Francine Chingcuanco et al. ANNALS OF INTERNAL MEDICINE
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis
- (2016) Patompong Ungprasert et al. CLINICAL RHEUMATOLOGY
- Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA
- (2016) Aoibhlinn O’Toole et al. DIGESTIVE DISEASES AND SCIENCES
- Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis
- (2016) Ennio Lubrano et al. DRUGS
- Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
- (2016) Stefanos Bonovas et al. Expert Opinion On Drug Safety
- A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
- (2016) M. Cutolo et al. JOURNAL OF RHEUMATOLOGY
- Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors
- (2016) E. Lubrano et al. JOURNAL OF RHEUMATOLOGY
- Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study
- (2016) Fabio Massimo Perrotta et al. POSTGRADUATE MEDICINE
- Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis
- (2016) Patompong Ungprasert et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network
- (2016) Hélène Vallet et al. Arthritis & Rheumatology
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
- (2015) L Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
- (2015) Monika M Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
- (2015) Sarah S. Thomas et al. BIODRUGS
- Infection risk associated with anti-TNF-α agents: a review
- (2015) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- Certolizumab pegol for the treatment of psoriatic arthritis
- (2015) Renata Baronaite Hansen et al. Expert Review of Clinical Immunology
- Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system
- (2015) Koichi Yanaba et al. JOURNAL OF DERMATOLOGY
- Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study
- (2015) Laura C. Coates et al. JOURNAL OF RHEUMATOLOGY
- Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs
- (2015) Fabio Massimo Perrotta et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Minimal Disease Activity and Anti-Tumor Necrosis Factor Therapy in Psoriatic Arthritis
- (2015) Amir Haddad et al. ARTHRITIS CARE & RESEARCH
- Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
- (2014) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
- (2014) Christopher Ritchlin et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease
- (2014) Ignazio Olivieri et al. AUTOIMMUNITY REVIEWS
- TNF-α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-α Treatment in Psoriatic Arthritis
- (2014) Giuseppe Murdaca et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis
- (2014) P. Nash et al. JOURNAL OF RHEUMATOLOGY
- Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response
- (2014) P. S. Helliwell et al. JOURNAL OF RHEUMATOLOGY
- Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
- (2014) Philip Helliwell et al. ARTHRITIS CARE & RESEARCH
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
- (2013) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
- (2013) D. Gladman et al. ARTHRITIS CARE & RESEARCH
- The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
- (2012) Philip S Helliwell et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis
- (2012) Vincent W. Lin et al. ARCHIVES OF DERMATOLOGY
- Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
- (2012) Georg Schett et al. Nature Reviews Rheumatology
- A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis
- (2011) Zoe Ash et al. ANNALS OF THE RHEUMATIC DISEASES
- Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
- (2011) B. B. Aggarwal et al. BLOOD
- Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease
- (2011) R. PEREZ ALAMINO et al. JOURNAL OF RHEUMATOLOGY
- Beyond Early Diagnosis: Occult Psoriatic Arthritis
- (2010) C. PALAZZI et al. JOURNAL OF RHEUMATOLOGY
- Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study
- (2010) D. D. GLADMAN et al. JOURNAL OF RHEUMATOLOGY
- Patient-reported Outcomes in a Randomized Trial of Etanercept in Psoriatic Arthritis
- (2010) P. J. MEASE et al. JOURNAL OF RHEUMATOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data
- (2010) Laura C. Coates et al. ARTHRITIS CARE & RESEARCH
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
- (2009) L C Coates et al. ANNALS OF THE RHEUMATIC DISEASES
- Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
- (2009) F Van den Bosch et al. ANNALS OF THE RHEUMATIC DISEASES
- International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis
- (2009) Vinod Chandran et al. ARTHRITIS AND RHEUMATISM
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study
- (2009) Arthur Kavanaugh et al. ARTHRITIS AND RHEUMATISM
- Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
- (2008) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Do TNF-blockers reduce or induce uveitis?
- (2008) T. Cobo-Ibanez et al. RHEUMATOLOGY
- TNF-mediated inflammatory disease
- (2007) JR Bradley JOURNAL OF PATHOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started